Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 9/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 4/20 | 0.38 |
| ▸ | DRD4 | P21917 | 4/20 | 0.38 |
| ▸ | DRD3 | P35462 | 4/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | DRD5 | P21918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27555656 | 1.00 | ADRB3 (0.52) | ADRB3ADRB1ADRB2HTR1AHTR1D | |
| SCHEMBL6600472 | 0.93 | ADRB3 (0.62) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6280119 | 0.91 | ADRB3 (0.50) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6406655 | 0.91 | ADRB3 (0.50) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6447612 | 0.91 | ADRB3 (0.50) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6286558 | 0.91 | ADRB3 (0.50) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6280116 | 0.91 | ADRB3 (0.50) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6286567 | 0.91 | ADRB3 (0.50) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6406650 | 0.91 | ADRB3 (0.50) | ADRB3ADRB1ADRB2 | |
| SCHEMBL6283260 | 0.90 | ADRB3 (0.51) | ADRB3ADRB1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6797714-B2 | HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION | BAYER PHARMACEUTICALS CORPORATION | 2004-09-28 | — | — | US | disclosed |
| US-20030013705-A1 | Novel carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists | BAYER PHARMACEUTICALS CORPORATION | 2003-01-16 | — | — | US | disclosed |
| US-6469031-B1 | USEFUL IN THE TREATMENT OF CONDITIONS SUCH AS HYPER-TRIGLYCERIDAEMIA, HYPERCHOLESTEROLAEMIA AND IN LOWERING HIGH DENSITY LIPOPROTEIN LEVELS AS WELL AS IN THE TREATMENT OF ATHEROSCLEROTIC, CARDIOVASCULAR AND DIABETIC CONDITIONS | BAYER CORPORATION | 2002-10-22 | — | — | US | disclosed |
| EP-1040106-B1 | CARBOXYL SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA 3 ADRENORECEPTOR AGONISTS | BAYER AG (US) | 2002-08-28 | — | — | EP | disclosed |
| EP-1040106-A1 | CARBOXYL SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA 3 ADRENORECEPTOR AGONISTS | Bayer Corporation (US) | 2000-10-04 | — | — | EP | disclosed |
| WO-1999032476-A1 | CARBOXYL SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA 3 ADRENORECEPTOR AGONISTS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013705-A1 | Novel carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists | ADRB3, ADRB1, ADRB2 | ADRB3 1/4885ADRB1 2/4885ADRB2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.